Strs Ohio Sells 30,448 Shares of Gilead Sciences, Inc. $GILD

Strs Ohio reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 510,771 shares of the biopharmaceutical company’s stock after selling 30,448 shares during the period. Strs Ohio’s holdings in Gilead Sciences were worth $71,186,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the period. Quattro Advisors LLC bought a new position in Gilead Sciences during the fourth quarter worth $26,000. Wealth Preservation Advisors LLC raised its stake in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in Gilead Sciences during the 4th quarter valued at $28,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on GILD shares. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a research note on Monday, June 8th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Finally, Morgan Stanley lowered their price target on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $158.41.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This trade represents a 2.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 83,000 shares of company stock worth $10,824,500. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $131.27 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a 50-day moving average of $129.48 and a 200-day moving average of $134.56. Gilead Sciences, Inc. has a 52 week low of $107.75 and a 52 week high of $157.29. The company has a market capitalization of $162.98 billion, a price-to-earnings ratio of 17.88 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the previous year, the firm posted $1.81 earnings per share. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.